{"entity":{"id":"nct03067051","kind":"trial","name":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","aka":[],"tldr":"A phase 1/2 trial of Verteporfin in prostate cancer, run by SpectraCure AB, now recruiting.","summary":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System is a phase 1/2 interventional study registered as NCT03067051 by SpectraCure AB, with 66 participants planned, started 2017-03-21 and due to reach its primary completion in 2027-07-31. Interventions recorded: Verteporfin and SpectraCure P18 System.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03067051","url":"https://clinicaltrials.gov/study/NCT03067051"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["spectracure"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03067051","phase":"1/2","setting":"Open-label Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer","sponsor":"SpectraCure AB","enrolled":66,"outcomes":[]},"route":"/trials/nct03067051/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"spectracure","kind":"company","name":"SpectraCure","route":"/companies/spectracure/"}]}}